A first-of-its-kind cohort study has been launched to diagnose hepatocellular carcinoma (HCC) more accurately at an earlier stage in high-risk patients, and to predict an individual’s likelihood of developing it.
While potentially curative treatment is possible with early diagnosis, only 20% of cases are detected at a stage where cure is possible. The ELEGANCE* study, led by the National Cancer Centre of Singapore, addresses this urgent need for high-risk individuals and aims to develop a simpler but more accurate blood test for the early diagnosis of HCC that can be done at Family Medicine clinics – to replace the current dual modalities of 6-monthly ultrasound examination and serum alpha-fetoprotein.
*The Early Detection of HCC: miRNA, Microbiome and Imaging Biomarkers in the Evolution of Chronic Liver Disease in a High-Risk Prospective Cohort
Quantitative magnetic resonance images of the liver from six patients presenting with liver cancer produced by Perspectum’s LiverMultiScan, which will be used in a new study led by National Cancer Centre SingaporeImage credit: Mole DJ et al. Plos One. 2020;15(12):e0238568
The four-year-long study aims to enrol 2,000 participants at high risk of HCC to develop new tools for earlier diagnosis.
The study aims to improve patient outcomes by:
The research team is actively recruiting patients with chronic liver disease as validated by blood tests and imaging.
We invite family medicine physicians to recommend eligible patients to call the study hotline at 6326 6573.
Family medicine physicians who would like to find out more about the study, please contact the study’s coordinators at:Tel: 6326 6573Email: email@example.com
Subscribe to our mailing list to get the updates to your inbox